New nurse-led program aims to help breast cancer survivors overcome hormone therapy hesitation

NCT ID NCT05465408

Completed Symptom relief Sponsor: Massachusetts General Hospital Source: ClinicalTrials.gov ↗

First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This study tested a brief, nurse-led videoconference program designed to help breast cancer survivors who were hesitant or delayed in starting recommended hormone therapy. The program aimed to address cultural and personal concerns. Researchers measured how many people enrolled, completed sessions, and reported satisfaction. The goal was to see if this approach is feasible and acceptable, not yet to prove it works.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: Culturally aware behavioral intervention (nurse-led videoconference sessions)
What this could lead to: If successful, this approach could help more breast cancer survivors start and stick with hormone therapy, potentially improving long-term outcomes.
What could go wrong: This is a small, early feasibility study with only 35 participants. It does not prove the intervention works on a large scale or improves survival.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for BREAST CANCER are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

breast cancer breast neoplasm hormone receptor-positive breast cancer Patient Compliance Treatment Adherence and Compliance Treatment Refusal

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

BREAST CANCER SURVIVORSHIP TREATMENT ADHERENCE TREATMENT COMPLIANCE TREATMENT REFUSAL

Contacts and locations

Locations

Dana-Farber Brigham Cancer Center - Foxborough

Foxborough, Massachusetts, 02035, United States
Dana-Farber Brigham Cancer Center at Milford Regional Medical Center

Milford, Massachusetts, 01757, United States
Dana-Farber Brigham Cancer Center with South Shore Hospital

Weymouth, Massachusetts, 02190, United States
Dana-Farber Cancer Institute

Boston, Massachusetts, 02215, United States
Dana-Farber Cancer Institute - Merrimack Valley

Methuen, Massachusetts, 01844, United States
Dana-Farber Cancer Institute at St Elizabeth's Medical Center

Brighton, Massachusetts, 02135, United States
Dana-Farber/New Hampshire Onoclogy-Hematology

Londonderry, New Hampshire, 03053, United States
Emerson Hospital/MGH Cancer Center

Concord, Massachusetts, 01742, United States
Mass General at Newton Wellesley Hospital

Newton, Massachusetts, 02462, United States
Mass General at North Shore Cancer Center

Danvers, Massachusetts, 01923, United States
Massachusetts General Hospital Cancer Center

Boston, Massachusetts, 02114, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.